Biohaven Announces Pricing of $225 Million Public Offering of Common Shares
Summary
NEW HAVEN, Conn. , Oct. 2, 2023 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today announced the pricing of its underwritten public offering of 10,227,273 of its common shares at a price to the public of $22.00 per share. Morgan, TD Cowen, Leerink Partners, and Piper Sandler are acting as the joint lead book-running managers of the offering, William Blair is acting as a book-runner of the offering and BTIG is acting as lead manager of the offering.The offering is being made only by means of a prospectus supplement and the accompanying prospectus, copies of which, when available, may be obtained from the offices of the following: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (866) 803-9204, or by email at prospectus-eq_fi@jpmchase.com , Cowen and Company, LLC, 599 Lexington Avenue, New York, NY 10022, by telephone at (833) 297-2926 or by email at Prospectus_ECM@cowen.com , Leerink Partners LLC, Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525, ext. The use of certain words, including "continue", "plan", "will", "believe", "may", "expect", "anticipate" and similar expressions, is intended to identify forward-looking statements. Actual results, developments and events may differ materially from those in the forward-looking statements as a result of various factors including: Biohavens ability to complete the offering of its common shares on the proposed terms, or at all, and Biohavens expectations related to the use of proceeds from the offering of its common shares. Additional important factors to be considered in connection with forward-looking statements are described in Biohavens filings with the Securities and Exchange Commission, including within the sections titled "Risk Factors" and "Managements Discussion and Analysis of Financial Condition and Results of Operations".